Published on : May 05, 2017
Albany, New York, May 05, 2017: The increasing need for cancer supportive care products is linked to the necessity of improving patient outcomes by providing greater tolerance to the side effects of cancer therapy regimens. To further elaborate the cancer supportive care therapeutics market, Market Research Hub (MRH) has recently added an analyzed report titled as “Global Cancer Supportive Care Therapeutics Market to 2022 - Patent Expirations Create Opportunities for Biosimilars in the Chemotherapy Induced Anemia and Neutropenia Markets” to its vast database. Based on the detailed report findings, the cancer supportive care market is forecast to grow at CAGR of 0.9%, from $11.7 billion in 2015 to $12.4 billion in 2022.
The cancer supportive care product market consists of drugs intended to prevent or treat the symptoms of cancer, and reduce the side effects of cancer treatments. The need to eradicate the after effect of cancer treatment and the urge to improve the quality of life of the patient has yielded more growth of the cancer supportive care therapeutic market. Moreover, the growth in the number of people diagnosed with cancer and access to effective treatment which allows patients to survive longer has increased the demand for safe and effective cancer supportive care drugs. The analyst has shown that there are 245 products in active development in the cancer supportive care pipeline. This continuous development of the cancer supportive drugs is proportionally increasing the market growth at the global level.
The report starts with the introduction of cancer therapy area, Epidemiology detailing cancer pain, chemotherapy side effects and oral mucositis, pathophysiology that consists of bone metastasis, oral mucositis, cancer pain, chemotherapy-induced nausea and vomiting, chemotherapy-induced anemia and chemotherapy-induced neutropenia. Further, the symptoms, diagnosis & grading along with treatment are carefully evaluated in the report for the benefit of the readers.
In the later section, the key marketed products are overviewed that includes Neulasta (pegfilgrastim), Xgeva (denosumab), Aranesp/Nesp (darbepoetin alfa), Xofigo (radium Ra 223 dichloride), Nucynta (tapentadol hydrochloride), Epogen/Procrit (epoetin alfa), Neupogen (Filgrastim) and Aloxi (palonosetron hydrochloride), Helsinn and Otsuka. The pipelined landscape is assessed in detail with development landscape, molecular targets, failure rate, and key pipeline products including Tanezumab by Pfizer and Eli Lilly and Rolontis (Eflapegrastim) by Spectrum Pharmaceuticals.
Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1065936
Finally, the market is forecasted based on overall market size, generic penetration, and revenue forecast by the molecular target. Major companies are deeply analyzed for revenue and market share, with main players including Amgen, Bayer, Heron Therapeutics, Insys Therapeutics, Kyowa Hakko Kirin, and Daiichi Sankyo.
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com